For example, the treatment study of Erchen decoction in nonalcoholic fatty liver disease (NAFLD) has shown that the interactions of active ingredients of Erchen decoction with 77 targets related to NAFLD mainly reduces inflammation’s stimulation of the liver through the TLR4 signaling pathway (Liu et al., 2021). This evidence concerns the gene TLR4 and metabolic dysfunction-associated steatotic liver disease.